Analyse des effets des inhibiteurs de l’aromatase en traitement prolongé chez les femmes ménopausées atteintes d’un cancer du sein non métastatique hormonodépendant ayant déjà reçu cinq ans d’hormonothérapie adjuvante : revue systématique et méta-analyse
- 6 March 2024
- journal article
- research article
- Published by Elsevier in Bulletin du Cancer
- Vol. 111 (4) , 356-362
Abstract
No abstract availableKeywords
Funding Information
- Santé
This publication has 15 references indexed in Scilit:
- Efficacy and toxicity of extended aromatase inhibitors after adjuvant aromatase inhibitors-containing therapy for hormone-receptor-positive breast cancer: a literature-based meta-analysis of randomized trialsBreast Cancer Research and Treatment, 2019
- Use of letrozole after aromatase inhibitor-based therapy in postmenopausal breast cancer (NRG Oncology/NSABP B-42): a randomised, double-blind, placebo-controlled, phase 3 trialThe Lancet Oncology, 2019
- Optimal Duration of Extended Adjuvant Endocrine Therapy for Early Breast Cancer; Results of the IDEAL Trial (BOOG 2006-05)JNCI: Journal of the National Cancer Institute, 2017
- Extending Aromatase-Inhibitor Adjuvant Therapy to 10 YearsNew England Journal of Medicine, 2016
- Observation versus late reintroduction of letrozole as adjuvant endocrine therapy for hormone receptor-positive breast cancer (ANZ0501 LATER): an open-label randomised, controlled trialAnnals of Oncology, 2016
- Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trialThe Lancet, 2013
- Extended Adjuvant Therapy With Anastrozole Among Postmenopausal Breast Cancer Patients: Results From the Randomized Austrian Breast and Colorectal Cancer Study Group Trial 6aJNCI: Journal of the National Cancer Institute, 2007
- Randomized Trial of Letrozole Following Tamoxifen as Extended Adjuvant Therapy in Receptor-Positive Breast Cancer: Updated Findings from NCIC CTG MA.17JNCI: Journal of the National Cancer Institute, 2005
- Measuring inconsistency in meta-analysesBMJ, 2003
- Five Versus More Than Five Years of Tamoxifen for Lymph Node-Negative Breast Cancer: Updated Findings From the National Surgical Adjuvant Breast and Bowel Project B-14 Randomized TrialJNCI: Journal of the National Cancer Institute, 2001